A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma

The study is being conducted to evaluate the safety and tolerability of SHR-3079, and to explore the Dose-limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of SHR-3079 in patients with B-cell non-Hodgkin lymphoma.

Trial Details

NCT ID
NCT07661537
Phase
PHASE1
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • SHR-3079 Injection
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Aged ≥ 18 years old;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1, expected survival ≥ 3 months;
  • Histologically confirmed B-NHL;
  • Participant population: Have received ≥ 1 line of standard anti-tumor treatment, and have not achieved response after the latest treatment or have …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →